These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26631880)

  • 1. A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment.
    Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H
    Intern Med; 2015; 54(23):2981-9. PubMed ID: 26631880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.
    Kodera R; Shikata K; Nakamura A; Okazaki S; Nagase R; Nakatou T; Haisa S; Hida K; Miyashita K; Makino H
    Intern Med; 2017; 56(6):605-613. PubMed ID: 28321057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes.
    Nishimura T; Meguro S; Sekioka R; Tanaka K; Saisho Y; Irie J; Tanaka M; Kawai T; Itoh H
    Diabetes Res Clin Pract; 2015 Jun; 108(3):441-7. PubMed ID: 25795273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
    Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
    BMC Endocr Disord; 2016 Dec; 16(1):70. PubMed ID: 27905912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the effect of seasonal administration on the efficacy of sitagliptin: Subanalysis of the Januvia Multicenter Prospective Trial in Type 2 Diabetes Study.
    Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
    J Diabetes Investig; 2018 Sep; 9(5):1159-1166. PubMed ID: 29427314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
    Scott R; Morgan J; Zimmer Z; Lam RLH; O'Neill EA; Kaufman KD; Engel SS; Raji A
    Diabetes Obes Metab; 2018 Dec; 20(12):2876-2884. PubMed ID: 30019498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus.
    Shankar RR; Xu L; Golm GT; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
    Int J Clin Pract; 2015 Jun; 69(6):626-31. PubMed ID: 25652751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics.
    Chen JF; Chang CM; Kuo MC; Tung SC; Tsao CF; Tsai CJ
    Diabetes Res Clin Pract; 2016 Oct; 120():8-14. PubMed ID: 27498072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.
    Umezawa S; Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Miyairi Y; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    BMC Endocr Disord; 2015 Jul; 15():34. PubMed ID: 26137940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.
    Kakara M; Nomura H; Ezaki M; Fukae M; Hirota T; Matsubayashi S; Hirakawa M; Ieiri I
    J Diabetes Complications; 2016; 30(7):1282-6. PubMed ID: 27338508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes.
    Takatori S; Hamada Y; Tanaka A; Akiyama S; Namba H; Tanaka M; Kawasaki H; Araki H
    Clin Ther; 2016 Feb; 38(2):398-403. PubMed ID: 26804641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.
    Nakamura T; Iwanaga Y; Miyaji Y; Nohara R; Ishimura T; Miyazaki S;
    Cardiovasc Diabetol; 2016 Mar; 15():54. PubMed ID: 27036865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of sitagliptin vs sulphonylureas in older people.
    Sharma M; Nazareth I; Petersen I
    Age Ageing; 2019 Sep; 48(5):725-732. PubMed ID: 31250890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
    Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
    Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.